Promising cancer combo study halted early

NCT ID NCT05580770

First seen May 02, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study tested a combination of two drugs, mirdametinib and BGB-3245, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drugs could shrink tumors. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Calvary Mater Newcastle

    Waratah, 2298, Australia

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas, 75246, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • Yale-New Haven Hospital-Yale Cancer Center

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.